129 reports of this reaction
2.0% of all FINGOLIMOD reports
#10 most reported adverse reaction
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY is the #10 most commonly reported adverse reaction for FINGOLIMOD, manufactured by Apotex Corp.. There are 129 FDA adverse event reports linking FINGOLIMOD to PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY. This represents approximately 2.0% of all 6,602 adverse event reports for this drug.
Patients taking FINGOLIMOD who experience progressive multifocal leukoencephalopathy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY is a less commonly reported adverse event for FINGOLIMOD, but still significant enough to appear in the safety profile.
In addition to progressive multifocal leukoencephalopathy, the following adverse reactions have been reported for FINGOLIMOD:
The following drugs have also been linked to progressive multifocal leukoencephalopathy in FDA adverse event reports:
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY has been reported as an adverse event in 129 FDA reports for FINGOLIMOD. This does not prove causation, but indicates an association observed in post-market surveillance data.
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY accounts for approximately 2.0% of all adverse event reports for FINGOLIMOD, making it a notable side effect.
If you experience progressive multifocal leukoencephalopathy while taking FINGOLIMOD, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.